212 related articles for article (PubMed ID: 35651316)
1. The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia.
Liu Y; Jang H; Zhang M; Tsai CJ; Maloney R; Nussinov R
Biophys J; 2022 Jun; 121(12):2251-2265. PubMed ID: 35651316
[TBL] [Abstract][Full Text] [Related]
2. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
3. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
4. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Million RP; Van Etten RA
Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
[TBL] [Abstract][Full Text] [Related]
6. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.
Odai H; Sasaki K; Iwamatsu A; Nakamoto T; Ueno H; Yamagata T; Mitani K; Yazaki Y; Hirai H
Blood; 1997 Apr; 89(8):2745-56. PubMed ID: 9108392
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo.
Peng Z; Yuan Y; Li YJ; Wang HX; Shi J; Cao WX; Luo HW; Deng JR; Feng WL
Int J Biochem Cell Biol; 2012 Jun; 44(6):861-8. PubMed ID: 22349215
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.
Kardinal C; Konkol B; Lin H; Eulitz M; Schmidt EK; Estrov Z; Talpaz M; Arlinghaus RB; Feller SM
Blood; 2001 Sep; 98(6):1773-81. PubMed ID: 11535511
[TBL] [Abstract][Full Text] [Related]
9. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
[TBL] [Abstract][Full Text] [Related]
10. NHD2-15, a novel antagonist of Growth Factor Receptor-Bound Protein-2 (GRB2), inhibits leukemic proliferation.
Lewis TR; Smith J; Griffin K; Aguiar S; Rueb KF; Holmberg-Douglas N; Sampson EM; Tomasetti S; Rodriguez S; Stachura DL; Arpin CC
PLoS One; 2020; 15(8):e0236839. PubMed ID: 32780746
[TBL] [Abstract][Full Text] [Related]
11. High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.
Feller SM; Tuchscherer G; Voss J
Leuk Lymphoma; 2003 Mar; 44(3):411-27. PubMed ID: 12688310
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
13. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
14. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
[TBL] [Abstract][Full Text] [Related]
15. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
Sha F; Gencer EB; Georgeon S; Koide A; Yasui N; Koide S; Hantschel O
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14924-9. PubMed ID: 23980151
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
Li S; Couvillon AD; Brasher BB; Van Etten RA
EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
[TBL] [Abstract][Full Text] [Related]
17. The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
Ye YB; Lin JY; Chen Q; Liu F; Chen HJ; Li JY; Liu WQ; Garbay C; Vidal M
Biochem Pharmacol; 2008 Jun; 75(11):2080-91. PubMed ID: 18455151
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells.
Modi H; Li L; Chu S; Rossi J; Yee JK; Bhatia R
Leukemia; 2011 Feb; 25(2):305-12. PubMed ID: 21072043
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
Tari AM; Arlinghaus R; Lopez-Berestein G
Biochem Biophys Res Commun; 1997 Jun; 235(2):383-8. PubMed ID: 9199202
[TBL] [Abstract][Full Text] [Related]
20. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.
Panigrahi S; Stetefeld J; Jangamreddy JR; Mandal S; Mandal SK; Los M
PLoS One; 2012; 7(1):e28395. PubMed ID: 22253690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
